Table 1. Haemodynamic parameters in N106-infused TAC mice.
| Baseline | 0.1 mg kg−1 | 1 mg kg−1 | 10 mg kg−1 | |
|---|---|---|---|---|
| ESPVR slope (mm Hg μl−1) | 3.13±0.09 | 9.04±1.20* | 11.26±1.00* | 20.3±0.41** |
| +dP/dtmax (mm Hg s−1) | 4738.76±68.90 | 4803.33±91.78 | 5448.83±147.09* | 6229.41±103.23** |
| Pmax (mm Hg) | 111.09±1.86 | 115.11±1.27 | 123.66±5.28* | 124.50±4.26* |
| τ (ms) | 7.69±0.13 | 7.50±0.15 | 6.40±0.15* | 6.27±0.13** |
| HR (bpm) | 422.13±10.23 | 417.11±4.54 | 422.33±3.79 | 455.08±5.62 |
+dP/dtmax LV maximal contraction rate (inotropic response); ESPVR, end systolic pressure–volume relationship; HR, heart rate; LV, left ventricle; N106, N-(4-methoxybenzo[d]thiazol-2-yl)-5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-amine; Pmax, maximal pressure; TAC, transverse aortic constriction; τ, time constant of isovolumetric relaxation
N106 treatment improves LV systolic function in a dose-dependent manner. Data are represented as mean±s.e.m. *P≤0.05; **P<0.001 versus baseline (n=10 mice per each group, Student's t-test).